Amid financial pressures and regulatory challenges linked to its gene therapy programs, Sarepta Therapeutics announced a strategic restructuring to reduce annual operating costs by approximately $400 million. The plan includes cutting roughly 36% of its workforce — about 500 employees — and pivoting towards siRNA-based therapies. Despite these cutbacks, the company projects continuing revenue from its Duchenne muscular dystrophy programs, with the gene therapy Elevidys expected to contribute significantly. Sarepta is concurrently addressing FDA requests for enhanced safety warnings and shipment pauses as it seeks to regain investor and patient confidence.